Introduction
Anabolic-androgenic steroids (AAS) are a group of hormones that include the natural male hormone, testosterone, together with a set of synthetic testosterone used clinically to treat several conditions such as reproductive system dysfunction, breast cancer, and anemia. AAS have, however, been used by some healthy men and more rarely by women, to gain muscle and lose body fat [1] . Nonmedical AAS use was primarily confined to elite athletes and bodybuilders in the 1960s who used it as a means to enhance performance [2] . In the last three decades, however, AAS use has spread into the general population [3] . Presently, AAS are been used worldwide by millions of men, many of whom having no athletic ambitions, wishing to increase and improve their physical strength and appearance [4e6] . Indeed, it has been suggested that elite athletes comprise the smallest group of AAS users [7] with higher levels of use occurring among such groups as recreational sportspeople [8] and those who use AAS for either occupational or aesthetic purposes [7, 9] .
In the short-term, AAS use seems to have few serious medical consequences, but in the long-term, it has generally been associated with several debilitating physical and psychological symptoms and increased mortality [3,7,10e14] . Before 1990, most prevalence studies of AAS use were conducted in North America [6] . However, more recent studies of the AAS epidemiology have been conducted outside North America [11,15e21] .
In spite of this, the worldwide prevalence of AAS use is poorly documented, and geographical distribution of studies concerning AAS use is mostly limited to the USA, Canada, Brazil, and some European countries [15] . In addition, although literature abounds on AAS use, no quantitative meta-analysis has been conducted on the global prevalence rate of AAS use. An analysis of this type is important because it can also be used to identify moderators of the prevalence rate. Against this backdrop, we conducted a metaanalysis on the global lifetime prevalence of AAS use. In addition to calculating an overall prevalence figure, we compared prevalence rates across sample type, gender, age, region, assessment method, sampling method, and publication year. Furthermore, we conducted a meta-regression analysis to investigate the predictive effect of the above study characteristics on the overall lifetime prevalence rate of AAS use.
Methods

Search strategy and inclusion criteria
A systematic and comprehensive literature search was conducted in PsycINFO, PubMed, ISI Web of Science, and Google Scholar for articles published between 1970 and July 2013. The following keywords: "anabol*," "steroid*," and "doping" were each used in combination with "preval*," "epidem*," and "incidence" for the search.
From an initial pool of 16,626 hits, 311 full-text articles were retrieved for further evaluation. After screening the 311 full-text articles for eligibility, 162 studies met the following key criteria for inclusion: (a) studies were published between 1970 and July 2013 (b) studies presented original data on the lifetime prevalence rate of AAS use, and (c) studies were published in English. Also, a manual check of the references of identified studies was conducted in search of potential unidentified studies. Searches were also conducted in online databases and Web sites for data on lifetime prevalence rates of AAS use in general population or household surveys, school surveys, government reports, and regional reports. Twenty-five new articles were identified through this grey literature search. Thus, a total of 187 articles were identified in the literature search.
Moreover, we were guided by the strategy of Calabria et al. [216, pg. 9] that "if data from a representative National study existed for a country, data from a study with a similar methodology and target age group were not included. In the United States, for example, the Monitoring the Future Continuing Study has provided extensive National survey results on American youth from 1975 to 2006. These National surveys cover the Global Burden of Disease target years, and therefore, studies that provided data for a similar population were not extracted. This decision was made to (a) avoid unnecessary duplicate year extractions and (b) address time restrictions." Hence, in the United States and related countries, we relied solely on the Monitoring the Future Surveys [181, 182] as representative of similar National surveys of AAS use among adolescents and youth. For European adolescents, we relied on the European School Survey Project on Alcohol and Other Drugs (ESPAD), a crossnational survey (of about 35 countries) conducted every fourth year since 1995 [162e166] . The literature search strategy adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [33] and followed the recommendation of the Meta-analysis of Observational Studies in Epidemiology (MOOSE) group [34] . Figure 1 presents the process of the search and selection of relevant studies.
Description of studies
Of the 187 articles identified, 16 articles [21,75,88,104,133, 146,168,171,173,174,176,181e183,199,200] presented prevalence rates of AAS use for 84 other original studies. Thus, a total of 271 separate studies were identified which provided data on lifetime prevalence rates of AAS use. The year of publication of the studies ranged from 1974 [217] to 2013 [23, 24, 37, 76, 167, 169, 172, 181, 182, 207] . Most studies were conducted in Western countries: North America (n ¼ 126), Europe (n ¼ 81), and Oceania (n ¼ 38), although 11 studies were conducted in Africa, seven in the Middle East, five in South America, and one in Asia. Two studies were transregional [154, 155] . The study characteristics are presented in Table 1 .
Data extraction and publication bias
During the literature search, the first author independently scrutinized and selected studies based on their titles, abstracts, and subject matter. Using a standardized data extraction form, the first author and another reviewer independently extracted data from the identified studies and coded them for potential moderators. Data extracted and coded included author name and publication year, country, and region of research, type of sample (prisoners and arrestees, recreational sportspeople, athletes, drug users, nonathletes, and high school), assessment method (questionnaires, interview, or both), sampling method (random or nonrandom), sample size (total, male, and female), age of participants (range, mean, and standard deviation), response rate, and lifetime prevalence rate of AAS use reported (male, female, and overall). To determine consistency between the two reviewers, an interrater reliability analysis using the Kappa statistic was performed in SPSS, version 20. The inter-reviewer reliability for the reviewers was found to be kappa ¼ 0.854 (P < .001) indicating an almost perfect agreement between the two reviewers [25] . Discrepant findings between the two reviewers were settled through discussion and further review of the article until consensus was reached.
A final table of all studies is presented in Table 1 . Publication bias was assessed visually by funnel plot and statistically by the trim and fill procedure [26] in Comprehensive Meta-Analysis version 2.0 (Biostat, Inc.) [27] . Under the random effects model, the point estimate and 95% confidence interval for the combined studies was [174] England and Wales General Q R 26,199 [174] England and Wales General Q R 28,407 [174] England and Wales General Q R 28,500 [174] England and Wales General Q R 28,975 [174] England and Wales General [174] England and Wales General Q R 28,330 [174] England and Wales General Q R 24,296 [174] England and Wales General Q R 23,331 [174] England and Wales General Q R 20,051 [174] England and Wales General Q R 12,852 [174] England and Wales General [174] England and Wales General Q R 10,813 3.3% (95% CI, 2.8e3.8). Applying the trim and fill function, these values were unchanged indicating the absence of publication bias. In addition, inspection of the funnel plot showed a symmetrical distribution of studies in terms of prevalences, confirming the absence of publication bias.
Statistical analysis
We performed a meta-analysis to estimate the global lifetime prevalence rate of AAS use. A random-effects model was used in the calculation of prevalence rates and 95% CIs. A random effects model is preferred because it is the most realistic assumption when the studies to be meta-analyzed cannot be reasonably considered as representative of the population of potential studies that have been conducted or can be conducted in the future about the research topic. Moreover, the random effects model allows a higher generalization of the results than the fixed effects model [27] . To assess the heterogeneity of the prevalences, the Q-statistic and the I 2 index were used. The Q-statistic is calculated by adding the squared deviations between the effect size of each study and the overall effect size weighted by the inverse variance for each study. The I 2 index on the other hand can be interpreted as the percentage of the total variability in a set of effect sizes due to true heterogeneity rather than chance [28] . We also performed subgroup analyses for all moderator variables separately based on the Q-statistic to assess the statistical significance of differences in prevalence rates between the subgroups using a random-effects model [29] . To reduce the probability of committing a type I error due to the high number of subgroup comparisons, Bonferroni correction was used. The metaanalysis was conducted using Comprehensive Meta-Analysis, version 2.0 [27] .
Moreover, to discover relevant moderator variables that could account for the variance in the overall prevalence rate, we performed a meta-regression analysis assuming a random effects model. The following moderator variables were included in the meta-regression analysis: publication year (1970e1979, 1980e1989, 1990e1999, 2000e2013) , region (Africa, Asia, Europe, Middle East, North America, Oceania, South America, and TransRegion), sample type (athletes, high school, drug users, nonathletes, prisoners and arrestees, recreational sportspeople), age range ( 19 years and >19 years), and studies with overlapping range of ages (trans-age range), sampling method (random and nonrandom), assessment method (interviews, questionnaires, or both) and the percentage of males in the sample (percentage of males in the sample >75%, percentage of males in the sample 50%, percentage of males in the sample >50% to 75%, and the percentage of males not provided). Because our independent variables were categorical, we dummy coded categories independently so that each level of the variable provided the basis for a dummy coded variable as 0 or 1. For each moderator variable, the category with the highest number of studies was used as a contrast. The metaregression analysis was conducted in SPSS, version 20 (IBM Corp.). For the meta-regression analysis, we used SPSS macros provided by Wilson [30] as the meta-regression module in Comprehensive Meta-Analysis 2.0 cannot handle categorical moderator variables.
Results
Overall prevalence rates and heterogeneity testing Table 2 presents the total number of studies, the prevalence rates and confidence limits, and the heterogeneity statistics (Q and I 2 ) for the overall population, males, and females.
From Table 2 , the overall prevalence rate obtained from 271 studies was 3.3% (95% CI, 2.8e3.8%, I
2 ¼ 99.7, P < .001). In addition, the prevalence rate for males, 6.4%, was significantly higher (Q bet ¼ 100.1, df ¼ 1, P < .001) than the prevalence rate for females, 1.6%.
Regional prevalence rates and heterogeneity testing Table 3 presents the total number of studies, the prevalence rates, and the confidence interval for the various geographical regions. Also presented are their respective heterogeneity statistics.
From Table 3 , the region with the highest overall prevalence rate of AAS use is the Middle East: 21.7%, followed by South America: 4.8%, Europe: 3.8%, North America: 3.0%, Oceania: 2.6%, Africa: 2.4%, and Asia: 0.2%. Moreover, overall prevalence rate for Trans-Regional studies was 6.0%. In addition, apart from Asia, the heterogeneity statistic (Q) for the overall prevalence rates, reached statistical significance (P < .001). Furthermore, we found from the subgroup comparisons that the prevalence rates in North America, Oceania, and Africa are significantly lower than the prevalence rate in the Middle East (Q NA ¼ 65.1, Q Oc ¼ 58.0, Q Afr ¼ 25.3, df ¼ 1, P < .001).
Prevalence rates for sample type and heterogeneity testing Table 4 presents the total number of studies, the prevalence rates and confidence limits, and the heterogeneity statistics in an order of hierarchy for the various sample types.
From Table 4 , recreational sportspeople had the highest overall prevalence rate: 18.4%, followed by athletes: 13.4%, prisoners and arrestees: 12.4%, and drug users: 8.0%. Moreover, prevalence rate for high-school students was 2.3%, whereas nonathletes had the lowest prevalence rate of 1.0%. In addition, the heterogeneity statistic (Q) for the overall prevalence rates for all sample types reached statistical significance (P < .001). From the subgroup comparisons, we found prevalence rates for high-school students and nonathletes to be significantly lower than prevalence rates among recreational sportspeople (Q HS ¼ 301. * P < .001. y p% is significantly lower than p% for males (P < .001). ns ¼ not significant; p% ¼ prevalence (%); Q ¼ heterogeneity statistic.
* P < .001. y p% is significantly lower than p% in the Middle East (P < .05).
Furthermore, the prevalence rate for nonathletes was significantly lower (Q bet ¼ 65.6, df ¼ 1, P < .001) than the prevalence rate for high-school students.
Prevalence rates for age range and heterogeneity testing Table 5 presents the total number of studies, the prevalence rates and confidence limits, and the heterogeneity statistics in an order of hierarchy for the age ranges.
From Table 5 , it can be seen that adolescents aged 19 years and younger have a higher overall prevalence rate: 2.5% than people aged older than 19 years: 1.9%. The prevalence rate for studies with a mix of participants in terms of ages (trans-age range) was 4.6%. Moreover, the heterogeneity statistic for the prevalence rates for all three groups, Q, reached statistical significance (P < .001). In addition, from the subgroup contrasts, the prevalence for adolescents aged 19 years and younger was significantly lower than that among the trans-age range group (Q bet ¼ 20.9, df ¼ 1, P < .001).
Prevalence rates for assessment method and heterogeneity testing Table 6 presents the total number of studies, the prevalence rates and confidence limits, and the heterogeneity statistics in an order of hierarchy for the assessment methods used in the research selected for this meta-analysis.
From Table 6 , it can be seen that studies that used only interviews had the highest overall prevalence rate: 11.1%, followed by studies that used only questionnaires: 3.0%, and studies that used both interviews and questionnaires: 1.8%. Moreover, the heterogeneity statistic for the overall prevalence rates of all assessment methods, Q, reached statistical significance (P < .001). From the subgroup comparisons, we found prevalence rates for studies that used only questionnaires or both interviews and questionnaires to be significantly lower than those for studies that used interviews only (Q Q ¼ 27.3, Q IQ ¼ 9.4, df ¼ 1, P < .001).
Prevalence rates for sampling method and heterogeneity testing Table 7 presents the total number of studies, the prevalence rates and confidence limits, and the heterogeneity statistics for sampling methods used in the various studies selected for this meta-analysis.
From Table 7 , studies that used nonrandom sampling methods had a significantly higher (Q bet ¼ 63.8, df ¼ 1, P < .001) overall prevalence rate, 11.4%, than studies that used random sampling methods, 2.4%.
Prevalence rates for publication year and heterogeneity testing Table 8 presents the total number of studies, the prevalence rates and confidence limits, and the heterogeneity statistics in an order of hierarchy for the publication years of the research selected for this meta-analysis.
From Table 8 , publication years 1970e1979 had the highest overall prevalence rate: 9.2%, followed by 1980e1989: 7.8%. Moreover, publication years 2000e2013 had a slightly higher prevalence rate, 3.2%, than 1990e1999: 2.9%. In addition, the heterogeneity statistic for the prevalence rates, Q, reached statistical significance (P < .001) for all publication years. Furthermore, from the subgroup comparisons, the prevalence rate for publication years 1990e1999 was significantly lower than prevalence rate for publication years 1970e1979 (Q bet ¼ 8.7, df ¼ 1, P < .001).
Meta-regression analysis
The large heterogeneity found in the overall AAS use prevalence rate suggests the existence of study characteristics influencing this variance. Consequently, we performed a meta-regression analysis to assess the predictive effect of publication year, region, sample type, assessment method (interview, questionnaire, or both), age range, sampling method (random and nonrandom), and the percentage of males in the sample on the overall prevalence rate of AAS use. Of these variables, sample type (athletes), assessment through only interview or both interview and questionnaire, sampling method (nonrandom), and percentage of males in the sample * P < .001. y p% is significantly lower than p% in recreational sportspeople (P < .001); p% is significantly lower than p% in athletes (P < .001); p% is significantly lower than p% in prisoners and arrestees (P < .001); p% is significantly lower than p% in drug users. z p% is significantly lower than p% in high school (P < .001). df (Q) ¼ Q's degrees of freedom; I 2 ¼ heterogeneity index; Q ¼ heterogeneity statistic; N ¼ number of studies; p% ¼ prevalence (%).
* P < .001. y p% is significantly lower than p% for trans-age range (P < .001). * P < .001. y p% is significantly lower than p% for interviews only (P < .01). * P < .001. y p% is significantly lower than p% for non-random sampling (P < .001).
(between 25% and 75%) were significantly related to the heterogeneity in the overall AAS use prevalence rate ( Table 9) .
Discussion
This article presents the very first meta-analysis of the global lifetime prevalence rate of AAS use. The overall lifetime prevalence rate across all studies was 3.3%. Moreover, from the subgroup comparisons, the overall lifetime prevalence rate for males, 6.4%, was significantly higher than the overall lifetime prevalence rate for females, 1.6%. This result corroborates the generally accepted position in the field [11, 16, 19, 31, 32] . In further support of this finding, the percentage of males in samples was significantly related to prevalence in the meta-regression analysis.
With reference to sample type, our finding that AAS use is most prevalent among recreational sportspeople and athletes surpassing prevalence rates among prisoners and arrestees, drug users, highschool students, and nonathletes is consistent with available evidence [8,39e41] . This result is also consistent with evidence suggesting that the odds of AAS use increases by about 91% with participation in at least one sport [42, 113] . Indeed, we confirmed the association of athletic involvement with AAS use in our metaregression analysis with sample type (athletes) significantly predicting AAS prevalence. Our finding with regards to prisoners and arrestees and drug users corroborates available evidence connecting AAS use to polydrug use in studies of prisoners and arrestees [35, 38, 84] and also general populations [36] .
In contrast to available evidence that most AAS users begin use in their 20s, leading to a significant increase in AAS use prevalence rate after the teenage years [44e46], we found that AAS use is more prevalent among teenagers than those older than 19 year. This finding may reflect a cohort effect.
Our finding that the regions with the highest overall rates of AAS use are the Middle East and South America is surprising but perhaps can be explained by the fact that most studies in these regions relied on self-reports from athletes and recreational athletes, a group among whom AAS use has been found to be highly prevalent [8, 40] . Again, our finding that Europe, North America, and Oceania have higher rates of AAS use than Africa and Asia is perhaps attributable to the fixation on "muscularity" as a definition of "masculinity" in Western cultures [14,47e49,64] . Still, in the metaregression analysis, region was insignificant suggesting that other factors better explained the variance in prevalence.
The meta-analysis showed that studies using nonrandom sampling methods reported a higher prevalence rate than studies based on random sampling methods is also explicable. This finding seems to be related to the fact that the predominance of nonrandomly selected samples comprised recreational sportspeople, athletes, prisoners, arrestees, and drug users among whom AAS use prevalence is relatively higher compared with high-school students and nonathletes, as previously found [8,38e40,50] . In further support of this finding, sampling method was significantly associated with prevalence in the meta-regression.
With reference to the assessment method, we found that studies using interviews reported a higher prevalence rate than studies using only questionnaires or both interviews and questionnaires. This finding is in part due to the fact that studies using interviews did not randomly select participants. More importantly, most respondents in these "interview studies" were prisoners, arrestees, recreational sportspeople, and athletes who, as indicated above, are notorious AAS users. Moreover, assessment method was found to be significant in the meta-regression analysis when we controlled for the other moderators.
Our finding that AAS use was most prevalent in the 1970s is comprehensible because two [22, 217] of the three studies conducted in the 1970s in this meta-analysis sampled elite athletes who were the predominant users of AAS in the 1970s [4] . Moreover, our finding that AAS use was most prevalent in the 1980s compared with the 1990s and 2000s supports the reports that AAS began to spread beyond the elite athletic community and into the general population in the 1980s [4, 51] . The authors of these studies suggest that the increase in AAS use during this period is due in part to the proliferation of underground guides [52, 53] , which offered detailed guidance on AAS use coupled with the fact that AAS were still readily available as prescription drugs with minimal federal enforcement until 1991 [54] .
Moreover, our finding that the prevalence rate of AAS use is slightly higher in recent times (after 2000) than in the 1990s suggests that nonmedical use of AAS has steadily increased since the * P < .001. y p% is significantly lower than p% in the 1970s (P < .008). 1990s. The significant drop in the AAS use prevalence rate between 1990 and 1999 compared with the 1980s is perhaps attributable to concern over AAS use and the enactment of legislation against AAS use in the 1990s [55] such as the Anabolic Steroid Control Act of 1990 in the United States [54] , the 1991 Act Prohibiting Certain Doping Substances in Sweden [219] , and other similar legislation enacted in other countries since the 1990s. Moreover, when we controlled for other moderator variables in the meta-regression analysis, publication year was not a significant moderator variable. This study, to our knowledge, is the first to have systematically examined the global lifetime prevalence rate of AAS use by a quantitative meta-analytic approach. Thus, the prevalence estimates in the present study constitute the best currently available basis for policymaking and planning. The global nature of this research, the large number of included studies and participants, and the advanced analysis of the data using both meta-analysis and meta-regression analysis are also notable assets of the present study.
The present meta-analysis, however, has limitations worth noting when interpreting our results. First is the validity of prevalence rates reported in the studies included in our meta-analysis and its potential to overestimate or underestimate our final prevalence rates. Kanayama et al. [158] contend that prevalence rates of AAS use are sometimes exaggerated due to false-positive responses to poorly worded questions regarding "steroids" on anonymous questionnaires. They argue that some respondents, especially highschool students, answer that they have used "steroids" when in fact they have used some over-the-counter substance that they thought was a steroid. Indeed, with the explosion of the supplement market in the 1990s [119, 120] , it has become more difficult to determine whether a person is using AAS, an AAS derivative, or some other substance marketed to work like AAS [158] .
Moreover, the present study concerned the lifetime prevalence of AAS use. Lifetime prevalences will naturally be higher than current prevalence. It should be noted that lifetime prevalence estimates by their retrospective nature are more susceptible to recall bias than current prevalences [220] . Lifetime prevalences also cover a wider range of use (from days to many years) in contrast to current prevalence that addresses "here and now" use. Again, in contrast to current prevalences, lifetime prevalence estimates cannot be validated against objective measures (e.g., urine samples) [221] . Our final prevalence estimates should, therefore, be considered in the light of this limitation. Another limitation is the paucity of studies on AAS use prevalence in many world regions, particularly in Africa, Asia, the Middle East, and South America. Although nonmedical AAS use is a global problem [14, 56] , the preponderance of epidemiologic research is limited to North America and Europe. Moreover, although some studies have been carried out in a few countries in these regions, generalization to a large number of other countries in the same region may be problematic, especially when the only available studies have small sample sizes and are of poor methodological quality.
The results of our study have important consequences for policymakers, health care professionals, and researchers. Nonmedical AAS use is a major global public health problem that requires the attention of policymakers and researchers. Thus, efforts need to be made in all regions, especially in Africa, Asia, the Middle East, and South America, not only to avert this disparity but also to monitor trends in the incidence and prevalence of AAS use. This research provides a strong starting point that can be improved as new evidence emerges especially from currently underrepresented regions. In addition, self-report measures of AAS use varied across studies and researchers are encouraged to move toward a common standard for assessing AAS use in future studies. In this regard, researchers must endeavor to formulate questions that explain carefully to respondents that AAS does not refer corticosteroids or over-the-counter nutritional supplements. Researchers must also require respondents to name the AAS that they have used. Thus, false-positive responses could be minimized and more accurate rates of AAS prevalence can be estimated.
